How many investments has OUP (Osage University Partners) made?

OUP (Osage University Partners) has 118 tracked investments, 9 of which have exited via acquisition or IPO, including 3 dated in the last 24 months.

What stage does OUP (Osage University Partners) invest at?

OUP (Osage University Partners) invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is OUP (Osage University Partners)'s typical check size?

OUP (Osage University Partners) typically writes checks of $1M – $20M.

What sectors does OUP (Osage University Partners) focus on?

OUP (Osage University Partners) focuses on AI & Machine Learning, Biotech, Cleantech, Climate Tech, Cloud Computing, Cybersecurity, Deep Tech, Digital Health, Energy, Enterprise Software, Hardware, Healthtech, Medical Devices, New Materials, Quantum Computing, SaaS, Sector Agnostic, Semiconductors.

Where is OUP (Osage University Partners) located?

OUP (Osage University Partners) is headquartered in Bala Cynwyd, US.

Does OUP (Osage University Partners) lead rounds?

Yes, OUP (Osage University Partners) leads investment rounds.

Who does OUP (Osage University Partners) co-invest with?

OUP (Osage University Partners) most often shares deals with ARCH Venture Partners, F-Prime Capital, Canaan Partners, among 198 tracked co-investors.

OUP (Osage University Partners)

Venture capital

Bala Cynwyd · Pre-Seed–Late Stage · 23 people tracked

Also known as Osage University Partners · OUP MANAGEMENT CO., LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

OUP backs startups commercializing transformational deep-technology innovations that emerge from or are inspired by breakthrough scientific research. For over 15 years the firm has focused specifically on science-driven companies, drawing on a team of former scientists, consultants, and operators to help founders convert laboratory discoveries into market-ready products. It emphasizes expertise in university tech transfer ecosystems, working closely with TTOs, principal investigators, and students. As a long-term partner, OUP reserves meaningful capital for follow-on rounds and connects portfolio companies to a network of Fortune 500 leaders, strategic partners, founders, and other investors to support commercial growth.

Source: firm website, verified Aug 25, 2026.

Stage

Pre-Seed–Late Stage

Check

$1M – $20M

Bala Cynwyd, Pennsylvania, US

Leads rounds

Leads

Instruments

Equity

Founded

2009

AUM

$800M

VC funds

Tracked investments

121

Team · 23 people

from the firm's website & curated & public directories

Anna Turetsky· General Partner, PxB Fund· New York, New York, United Statesin

Anna Turetsky joined OUP in 2025 as General Partner of the $50M PxB Fund (Penn-BioNTech Innovative Therapeutics Seed Fund), focusing exclusively on life science companies emerging from University of Pennsylvania technologies. She previously launched and led the venture investing arm of the Mark Foundation for Cancer Research and began her career at Lightstone Ventures. She holds a Ph.D. in Biophysics from Harvard University and a B.A. in Biochemistry from the University of Pennsylvania.

Louis Berneman· Founding Partner· Naples, Florida, United Statesin

Louis Berneman heads Texelerate, LLC, a technology transfer consultancy specializing in startup investment, royalty monetization, and licensing transactions. He is founding partner emeritus of Osage University Partners and fund advisor emeritus to HealthCare Royalty Partners, with prior experience as managing director of the Center for Technology Transfer at the University of Pennsylvania. Over 30 years, he has worked in intellectual property licensing, business development, and entrepreneurial activities, and holds certifications as a Licensing Professional and Registered Technology Transfer Professional.

l•••@oup.vcreveal

Manny Stockman· Managing Partner· Greater Philadelphiain 𝕏

Manny Stockman is Managing Partner at Osage University Partners, a venture capital fund that invests in technology spinouts from partner universities across the US, Canada, Israel, and the UK. His investment portfolio spans deep technology across computing, sensing, materials, and software sectors, including companies such as SiFive, IonQ, NuMat, Censys, and Delfi Diagnostics.

m•••@oup.vcreveal

Matt Cohen· Managing Partner· Philadelphia, Pennsylvaniain 𝕏

Matt Cohen is Managing Partner at Osage University Partners, a venture capital firm investing in innovative technologies derived from university research. He previously worked as a management consultant on projects spanning growth strategy, portfolio prioritization, commercialization planning, and commercial due diligence across multiple industries. Cohen has extensive knowledge of vaccine, immunologic, biologic, and small molecule therapeutic approaches in U.S., European, Brazilian, and Asian markets, with investments in numerous biotechnology companies including PMV Pharmaceuticals, Kura Oncology, Biohaven Pharma, Beam Therapeutics, and Sana Biotechnology.

m•••@oup.vcreveal

Robert Adelson· Managing Partner· Merion, PAin

Robert Adelson runs complementary early-stage B2B SaaS and university-spinout funds, combining corporate law and 1990s buyout experience with long-tenure VC insight and a 50-year university-ecosystem focus.

r•••@osagepartners.comreveal

Kirsten Leute· Partner· Los Altos, California, United Statesin 𝕏

Kirsten Leute has 19 years of experience in technology transfer, including roles at Stanford University and the German Cancer Research Center. Before joining OUP, she served as Associate Director at Stanford's Office of Technology Licensing, where she managed portfolios of inventions across many technology areas with a concentration in biotechnology. She is a former two-time board member of the Association of University Technology Managers and co-founded Equalize Startups, a nonprofit supporting women-led startups.

k•••@oup.vcreveal

Mitra Miri· Partner· United Statesin 𝕏

Principal on OUP's life science team, focused on working with scientific and academic founders in the early stage.

m•••@oup.vcreveal

Allen Chen· Principal· New York, New York, United Statesin

Allen Chen is a Principal on the technology investment team at Osage University Partners, focusing on software, hardware, and computing. Before OUP, he spent four years at BMW i Ventures leading early-stage investments in robotics, critical minerals, cybersecurity, and enterprise software, and held operating roles at Uber and Lilium. He started his career as a strategy consultant at L.E.K. Consulting and holds a BBA from Emory University.

a•••@oup.vcreveal

Ajay Rayasam· Principal· San Francisco Bay Areain 𝕏

Ajay Rayasam joined Osage University Partners in 2021 as an associate on the technology investment team, focusing on software, computing, and hardware opportunities. He previously served as Chief of Staff and Product Manager at enterprise software startup Kubisys, and holds an M.S. from MIT and a B.Sc. from Babson College.

a•••@oup.vcreveal

Beth Grafstrom· Senior Vice Presidentin

Beth Grafstrom joined OUP in 2015. She previously worked at New Mountain Capital as a Private Equity Fund Accountant and later as the Business Development Company Controller, and before that was a Senior Associate in the Banking Capital Markets Assurance practice at PricewaterhouseCoopers. She holds a B.S. from the University of Scranton and is a New York State CPA.

b•••@oup.vcreveal

Britt Kennett· Senior Executive Assistant· King of Prussia, PAin

Britt Kennett joined OUP as an Executive Assistant in 2015. Before that, she spent about ten years at D.A. Kreuter Associates, an executive search firm focused on financial services, where she served as Director of Client Services. She holds a BA in Psychology from Villanova University.

b•••@oup.vcreveal

Brittany de Kouchkovsky· Director, University Relations· San Diego, California, United Statesin

Brittany de Kouchkovsky is Director at Osage University Partners, where she works on startup sourcing and development. She has experience in life sciences venture investment, biotech venture creation, academic technology sourcing, and early-stage therapeutic operations and development.

b•••@oup.vcreveal

Chris Nawalinski· Fund Accountant· Morrisville, Pennsylvania, United Statesin

Claudia Dunnous· Chief Financial Officer· Philadelphia, Pennsylvania, United Statesin

Claudia Dunnous joined Osage Partners in 2006 and is a CPA with over 25 years of experience across private equity, retail, and manufacturing. She previously served as Vice President of Finance and Operations at Hamburger Color Company, a privately held manufacturer, where she led its sale to a strategic buyer, and earlier provided accounting and business advisory services at Grant Thornton and Laventhol and Horwath. She holds a BA in Economics from Brandeis University and an MBA in Accounting from Drexel University.

c•••@osagepartners.comreveal

Jaimie Testai· King of Prussia, Pennsylvania, United Statesin

Edited the interview for the OUP blog series.

Kayti Mangels· Executive Assistant and Program Coordinator· Philadelphia, PAin

Kayti Mangels joined OUP as an Administrative Assistant in 2021. Previously, she supported the Office Manager and COO at Golden Eagle Coin, and before that spent three years as an elementary school teacher in North Philadelphia. She holds a B.S. in Early Childhood Education with a minor in Special Education from Chestnut Hill College.

k•••@oup.vcreveal

Kumar Patel· Fund Controller· Greater Philadelphiain

Kumar Patel joined Osage University Partners in 2019. He previously worked as a Senior Fund Accountant at The Rock Creek Group and as a Supervisor at SEI Investments. He holds a B.A. in Accounting from Arcadia University and is a CPA.

k•••@oup.vcreveal

Sami Nabil· Analyst· Philadelphia, Pennsylvania, United Statesin

Sami Nabil is an Analyst at Osage University Partners, which he joined after nearly two years as a co-op with the firm. He works across the investment lifecycle, including fund operations, deal sourcing, and diligence. Before OUP, he was an Industrial Engineering Co-op at The Estée Lauder Companies, and he graduated magna cum laude from Drexel University with a B.S. in Physics, where he conducted neutrino physics research; he is also a deferred MBA admit at Columbia Business School.

Justin Robeny· Associate· New York, New York, United Statesin

Justin Robeny joined Osage University Partners in 2024 as an associate on the life sciences team, focusing on biotech investments across therapeutic areas. He previously was an analyst at Octagon Capital Advisors covering oncology and immunology healthcare investments, and worked in clinical operations at Axsome Therapeutics. He holds an M.Sc. in clinical research from the Icahn School of Medicine at Mount Sinai and a B.A. in human health from Emory University.

j•••@oup.vcreveal

Marc A. Singer· Managing Partner· Greater Philadelphiain

Managing Partner focused on technology investments at OUP, contributing perspectives on early- and late-stage VC selection.

m•••@oup.vcreveal

Nabil Ullah· Associate· Greater Philadelphiain

Author of the OUP insights article on startup equity allocation for academic spinouts.

n•••@oup.vcreveal

William Harrington· Managing Partner· Philadelphia, Pennsylvaniain

Bill Harrington joined OUP in 2012 and, as a Managing Partner, oversees the firm's life science investment activities and shares day-to-day execution responsibilities. He previously spent over a decade as a General Partner at Three Arch Partners investing in therapeutics, medical devices, and healthcare services, and earlier practiced as an interventional radiologist. He holds a BS from Tufts, an MD from Harvard Medical School, an MBA from UC Berkeley, and the CFA designation.

b•••@oup.vcreveal

David R. Williams· Analyst· Naperville, Illinois, United Statesin

What they invest in

from 78 of 121 portfolio companies

Biotech ×47Healthtech ×26AI & Machine Learning ×20Medical Devices ×17Deep Tech ×12Hardware ×10Enterprise Software ×8Digital Health ×7

HQs:United States×75Israel×2

Who they back

founder profiles across 58 portfolio companies

48%

solo founders

28 of 58 mapped founding teams

33%

repeat founders

of 15 founders with career history

~2 yrs

old at investment

median across 13 dated deals

Founding team size:solo founder×282 founders×163 founders×94+ founders×5

Where their founders studiedfrom 14 founders with education data

Massachusetts Institute of Technology ×2University of California, Berkeley ×2

Where their founders worked beforefrom 15 founders with career history

University of Washington ×3

Investments · 121 tracked

founders shown can be your intro path

By year:2025 · 2 2024 · 1 2022 · 1 2021 · 1 2020 · 2 2019 · 1 2018 · 2 2017 · 1 2016 · 1 2015 · 1 2012 · 114 dated

Ambiqambiq.com in 𝕏NYSE: AMBQ

Ambiq develops ultra-low-power semiconductor solutions and edge AI platforms for IoT and healthcare applications.

AI & Machine LearningIoTSemiconductorsAustin, US

Scott Hanson(Executive Officer, Director)inDennis Sylvester(Director)inFumihide Esaka(CEO)inScott Goodwin(Executive Officer)inJoseph A. Tautges(Director)Paul Rolls(Executive Officer)

Co-investorsCisco Investments Conductive Ventures Kleiner Perkins Matter Venture Partners Mercury Fund Soul Capital +3 more

Beam Therapeuticsbeamtx.com in 𝕏NASDAQ: BEAMNov 2018

Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.

BiotechDeep TechMedical DevicesCambridge, US

David R. Liu(Founder and Inventor)inJ. Keith Joung(Founder and Inventor)inFeng Zhang(Founder and Inventor)David R. Liu, Ph.D.(Founder and Inventor)J. Keith Joung, M.D., Ph.D.(Founder and Inventor)Feng Zhang, Ph.D.(Founder and Inventor)

Co-investorsARCH Venture Partners Dreamers VC Eight Roads Ventures F-Prime Capital Foresite Capital GV (Google Ventures)+1 more

Evolv TechnologiesNASDAQ: EVLV

Waltham, US

Anil Chitkara(Executive Officer)Michael Ellenbogen(Executive Officer, Director)Kevin O'Brien(Executive Officer)

BoardJoel Cutler(Director)Patrick Ennis(Director)Bilal Zuberi(Director)in

Co-investorsDCVC (Data Collective)Lux Capital

Guardant Healthguardanthealth.com in 𝕏NASDAQ: GH

Guardant Health develops blood-based testing (liquid biopsy) for cancer detection and monitoring across all stages of the disease.

BiotechDigital HealthHealthtechMedical DevicesRedwood City, US

AmirAli Talasaz(Executive Officer, Director)inHelmy Eltoukhy(Executive Officer, Director)inMichael Wiley(Executive Officer)in

BoardWarren Hogarth(Director)Samir Kaul(Director)in

Co-investors8VC AUTHENTIC VENTURES Cota Capital Felicis Ventures Khosla Ventures Lightspeed Venture Partners +6 more

IonQNYSE: IONQ

Kura Oncologykuraoncology.com inNASDAQ: KURA

Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.

BiotechDigital HealthMedical DevicesLa Jolla, US

TROY WILSON(Executive Officer, Director)inPINGDA REN(Executive Officer)inYI LIU(Executive Officer)inTroy Wilson(Founder)inHEIDI HENSON(Executive Officer)inANNETTE NORTH(Executive Officer)

Co-investorsARCH Venture Partners Avoro Capital Advisors EcoR1 Capital Foresite Capital Nextech Invest

Precision BioSciencesprecisionbiosciences.com in 𝕏NASDAQ: DTIL

Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

BiotechDeep TechHealthtechDurham, US

DEREK JANTZ(Executive Officer, Director)inMATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)inDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)in

BoardROBERT ADELMAN(Director)

Co-investorsage1 Aliment Capital Brace Pharma F-Prime Capital OCV Partners Pontifax AgTech +4 more

Prime Medicineprimemedicine.com in 𝕏NASDAQ: PRME

Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.

BiotechDeep TechHealthtechMedical Devices

Andrew Anzalone(Co-founder and Head of Platform)David Liu(Co-founder)Allan Reine(Chief Executive Officer)inMohammed Asmal(Chief Medical Officer)inAnn Lee(Chief Technical Officer)Svetlana Makhni(Chief Financial Officer)

Co-investorsARCH Venture Partners GV (Google Ventures)Newpath Partners F-Prime Capital Samsara BioCapital

Q32 Bioq32bio.com in 𝕏NASDAQ: QTTB

Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.

BiotechHealthtech

Shelia Violette(Founder & Chief Scientific Officer)Michael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)David Appugliese(Senior Vice President, Head of People)

Co-investorsAtlas Venture OrbiMed CU Healthcare Innovation Fund Sanofi Ventures Agent Capital

Sera Prognosticsseraprognostics.com in 𝕏NASDAQ: SERA

Sera Prognostics develops women's health diagnostics focused on pregnancy, including the PreTRM blood test that predicts an individual's risk of spontaneous preterm birth in singleton pregnancies and the LikeMine platform that compares pregnancy outcomes using U.S. pregnancy data.

BiotechDigital HealthFemTechHealthtechSalt Lake City, US

Douglas Fisher(Executive Officer)Jay Moyes(Executive Officer)inGregory C. Critchfield(Executive Officer, Director)inAndrew A. Sauter(Executive Officer)in

BoardMansoor Mirza(Director)Ryan M. Trimble(Director)

Co-investorsaMoon Excelestar Ventures UpStart Ventures Vivo Capital Catalyst Health Ventures Domain Associates

Spero Therapeuticssperotherapeutics.com inNASDAQ: SPRO

Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.

BiotechCambridge, US

Ankit Mahadevia(Executive Officer, Director)inStephen Garbacz(Executive Officer)in

BoardJean-Francois Formela(Director)inReza Halse(Director)Casper Breum(Director)Vikas Goyal(Director)

Co-investorsHEALTHCARE ROYALTY PARTNERS MRL Ventures Fund RA Capital Alphabet Atlas Venture

Veradermicsveradermics.com inNYSE: MANE

Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.

BiotechHealthtechWest Hartford, US

Reid Waldman(Chief Executive Officer and Board Member)inTim Durso(Chief Technical Officer)inDominic Carrano(Chief Financial Officer and Treasurer)inMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)

Co-investorsLongitude Capital Connecticut Innovations SR One Capital Management

Vor BiopharmaNASDAQ: VOR

Co-investors5AM Ventures RA Capital

Eridueridu.ai in 𝕏✓ verified

Eridu develops networking infrastructure optimized for artificial intelligence workloads.

AI & Machine LearningCloud ComputingDeep TechHardwareSaratoga, US

Drew Perkins(CEO and founder)inBrian Kinard(Executive Officer)in

BoardJagdeep Singh(Director)Dipender Saluja(Director)Wen Hsieh(Director)Christian Gallagher(Director)

Co-investorsBosch Ventures Catapult Ventures Matter Venture Partners Socratic Partners Zelda Ventures Black Opal Ventures +12 more

Aeriepharmaaeriepharma.com in

Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.

BiotechHealthtechMedical DevicesBedminster, US

CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)

BoardANAND MEHRA(Director)

Co-investorsAlta Partners Avoro Capital Advisors Foresite Capital Sofinnova Ventures

Aerovate Therapeutics

Boston, US

Co-investorsRA Capital

Agita Labsagitalabs.comDec 2020

Agita Labs develops hardware security and computer architecture technology focused on secure computation and side-channel resistance techniques.

CybersecurityDeep TechHardwareAnn Arbor, US

Valeria Bertacco(Co-founder)Todd Austin(Co-founder)Amy Wirth(Chief Financial Officer)Lip-Bu Tan(Director)

AGTC

Algorithmiaalgorithmia.com inAcquired

Algorithmia offers an enterprise AI platform for developing, deploying, and governing machine learning models and AI applications, with tooling tailored to roles across data science, engineering, DevOps, and IT teams.

AI & Machine LearningDeveloper ToolsEnterprise SoftwareSeattle, US

Kenneth F. Daniel(Executive Officer, Director)Diego M. Oppenheimer(Executive Officer, Director)in

BoardTimothy Porter(Director)inAnna Patterson(Director)in

Co-investorsGradient Ventures Madrona Venture Group Norwest Venture Partners Work-Bench

Alphina Therapeuticsalphinatx.com

Develops therapeutics targeting altered NAD metabolism in cancer, using IP licensed from Yale University.

BiotechNew Haven, US

Barbara Fox(Executive Officer, Director)Nicholas J Galli(Executive Officer, Director)Stanley Choy(Executive Officer)Ranjit Bindra(Director)

BoardColleen Cuffaro(Director)inMatthew Cohen(Director)in

Co-investorsCanaan Partners Connecticut Innovations HighCape Capital

Antiva Biosciencesantivabio.com in

Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.

BiotechFemTechHealthtechMedical DevicesRedwood City, US

Karl Y. Hostetler(Executive Officer, Director)inGail Maderis(Director)inKristine Ball(Executive Officer, Director)inElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRaju Gadiraju(Executive Officer)in

Co-investorsAdjuvant Capital Brace Pharma Canaan Partners Lumira Ventures MPM BioImpact Sofinnova Ventures +3 more

Aptinyxaptinyx.com

BiotechEvanston, US

Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)

BoardLiam Ratcliffe(Director)Terry P. Gould(Director)

Co-investorsBain Capital Life Sciences Frazier Life Sciences Latterell Venture Partners Longitude Capital Agent Capital HBM Healthcare Investments +2 more

Arrakis Therapeuticsarrakistx.com in 𝕏

Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.

AI & Machine LearningBiotechDeep TechHealthtechCambridge, US

Michael Gilman(Executive Officer, Director)Mark DeLong(CEO)inDavid Neafus(Executive Officer)Russell C. Petter(Executive Officer)

BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in

Co-investorsCanaan Partners Pfizer Ventures Advent Life Sciences Nextech Invest Pfizer Venture Investments venBio Partners +1 more

Arsenal Biosciencesarsenalbio.com

Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Ken Drazan(Founder)James Ahlers(Executive Officer)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)

BoardValentin Barsan(Director)Sean Parker(Director)

Co-investorsARCH Venture Partners Hitachi Ventures Kleiner Perkins SoftBank Vision Fund Westlake Village BioPartners

Artizan Biosciences

Asset Watchassetwatch.com in 𝕏

AssetWatch provides cloud-based asset monitoring software and sensor technology to help manufacturing and industrial facilities prevent unplanned equipment downtime.

Advanced ManufacturingEnterprise SoftwareIoTSaaSWesterville, US

William Zell(Executive Officer, Director)William Ruff(Executive Officer)inRobert Lee(Director)inTad Dritz(VP of Development)inJeff Haskett(COO)inBrian Graham(Executive Officer, Director)in

Co-investorsCerity Partners Ventures G2 Venture Partners Harmonic Growth Partners JobsOhio Ventures Monte Carlo Capital Triangle Peak Partners +4 more

Atsena Therapeutics

Co-investorsHatteras Venture Partners Lightstone Ventures

Avid Radiopharmaceuticals

Co-investorsBioAdvance Pfizer Venture Investments

BioAge

Biotechnology company developing drugs to treat aging and associated diseases

Co-investorsFelicis Ventures SV Health Investors

Biohaven Pharmaceuticalsbiohavenpharma.com in 𝕏

Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options.

BiotechHealthtech

Vlad Coric(Chairman & Chief Executive Officer)

Co-investorsAisling Capital APERTURE Venture Partners Connecticut Innovations

Blade Therapeutics

BiotechSouth San Francisco, US

Wendye Robbins(Executive Officer, Director)

BoardLuke Evnin(Director)inCameron Wheeler(Director)Peter van Vlasselaer(Director)Elaine Jones(Director)William Slattery(Director)

Co-investorsBay City Capital Pfizer Venture Investments +ND Capital MPM BioImpact

Body LabsAug 2015

New York, US

William J. O'Farrell(Executive Officer, Director)Michael Black(Director)

BoardJoseph Ferrara(Director)Lawrence Lenihan(Director)

Brimstonebrimstone.com inMar 2022

Brimstone develops co-production processes to manufacture cement, steel, aluminum, and other critical minerals from a single feedstock in an integrated facility.

Advanced ManufacturingCircular EconomyCleantechConstruction TechNew MaterialsOakland, US

Cody Finke(CEO)Hugo LeandriinCody Finke, Ph.D.(Founder)in

Co-investorsAccelr8 Collaborative Fund Creative Destruction Lab (CDL)DCVC (Data Collective)Fifth Wall GVP Climate +4 more

Capella Bioscience

Cardioxyl Pharmaceuticals

Cartesia

Cell Design Labscelldesignlabs.com

BiotechLafayette, US

Peter Emtage(Executive Officer)Greg Giotta(Executive Officer)Brian Atwood(Executive Officer, Director, Promoter)

BoardFred Cohen(Executive Officer, Director, Promoter)Brook Byers(Director)inArie Belldegrun(Director)

Co-investorsKleiner Perkins Mission Bay Capital

Censys

Chroma Medicine

Clarifaiclarifai.com in 𝕏

Clarifai developed AI inference technology and compute orchestration software for running and optimizing machine learning models at scale.

AI & Machine LearningCloud ComputingData & InfrastructureNew York, US

Matthew Zeiler(Executive Officer, Director)in

BoardAlbert Wenger(Director)in

Co-investorsBright Pixel Capital Corazon Capital GV (Google Ventures)Lux Capital Menlo Ventures New Enterprise Associates (NEA)+11 more

Clinipaceclinipace.com in

Caidya is a contract research organization (CRO) that provides scientific, medical, and operational support for clinical development and cross-border clinical trials.

BiotechDigital HealthHealthtechMorrisville, US

Mark Ubert(Executive Officer)Jesse Watson(Director)Brian Carney(Director)Jeff L. Williams(Executive Officer, Director)Melissa Daniels(Director)Christopher K. Porter(Executive Officer)

Co-investorsCreathor Ventures Hatteras Venture Partners

Coho Therapeutics

Corelightcorelight.com in 𝕏

Corelight provides network detection and response (NDR) software that uses agentic triage to automatically consolidate security alerts into entity-centric cases with evidence-backed investigation summaries.

AI & Machine LearningCybersecurityEnterprise Software

Seth Hall(Founder)in

Co-investorsAccel Cisco Investments Delta-v Capital Energy Impact Partners Flucas Ventures H.I.G. Capital +3 more

Cyteir Therapeuticscyteir.com in 𝕏

Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.

BiotechHealthtechCambridge, US

Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)inDonald Corcoran(Executive Officer, Director)inMarkus Renschler(Director)in

BoardTimothy Romberger(Director)Barry Mills(Director)

Co-investorsDroia Ventures Lightstone Ventures

Delfi Diagnosticsdelfidiagnostics.com in

DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US

Victor Velculescu(Executive Officer, Director, Promoter)inPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)in

BoardRishi Gupta(Director)in

Co-investorsAV8 Ventures Foresite Capital Illumina Ventures Menlo Ventures Open Field Capital OrbiMed +3 more

DICE Therapeutics

Clinical-stage biopharmaceutical company combining innovative chemistry with validated biology to make medicines more accessible for chronic autoimmune and inflammatory diseases.

Co-investorsSamsara BioCapital

Dracenpharmadracenpharma.com

Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment.

BiotechHealthtechBaltimore, US

Robert Wild(Co-founder & Chief Scientific Officer)Thomas M. Estok(Chief Executive Officer, President and Treasurer)Drew Pardoll, M.D., Ph.D.(Director)

BoardJonathan Leff(Director)Robert Jackson(Director)

Co-investorsBiotech Investments S.R.O Deerfield Management Company

E-scape Bio

BiotechSouth San Francisco, US

Julie Anne Smith(Executive Officer, Director)R. Sanders Williams(Director)Perry Karsen(Director)Judith Li(Director)Markus Goebel(Director)Peter Moldt(Director)

Effector Therapeuticseffector.com

eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.

BiotechSolana Beach, US

Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)

BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)

Co-investorsAstellas Venture Management LLC Mission Bay Capital Mission Biocapital Pfizer Venture Investments US Venture Partners Sofinnova Ventures

eGenesisegenesis.com

Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.

BiotechBrookline, US

Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)

BoardGeorge M. Church(Director)

Co-investorsAlta Partners ARCH Venture Partners Catalio Capital Management, LP Khosla Ventures b2venture Kendall Capital Partners

Einblick

Elementaryelementary-data.com in 𝕏

Elementary builds data observability tools that monitor data quality and reliability for modern data teams.

AI & Machine LearningData & InfrastructureDeveloper ToolsEnterprise SoftwareTel Aviv-Yafo, IL

Maayan Salom(Founder)inOr Avidov(Founder)in

Co-investorsModern Technical Y Combinator

Elementary Roboticselementaryrobotics.com in 𝕏

Elementary Robotics develops machine vision inspection systems for industrial quality control and defect detection.

Advanced ManufacturingAI & Machine LearningRobotics

Co-investorsRiot Ventures Thundermark Capital Ubiquity Ventures

Embodied

EnaChip

Eridu

Everactiveeveractive.com

Everactive develops ultra-low power, self-powered systems-on-chip (SoCs) for Ambient IoT devices that sense, process, and wirelessly transmit data using harvested environmental energy instead of batteries.

HardwareIoTSemiconductorsSan Jose, US

Benton Calhoun(Executive Officer, Director)inDavid Wentzloff(Executive Officer, Director)Brendan R Richardson(Executive Officer, Director)

BoardGeorge Kastendike(Director)Greg Papadopoulos(Director)Jack Busch(Director)

Co-investorsBlue Bear Capital Partners New Enterprise Associates (NEA)ABB Technology Ventures Osage University Partners

Exostellarexostellar.io

Co-investorsCambium Capital Candou Ventures Celesta Capital Celesta Capital Eastlink Capital Partners Launch NY+2 more

Faraday Pharmaceuticalsfaradaypharma.comDefunct

Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.

BiotechSeattle, US

Mark Roth(Executive Officer, Director, Promoter)Brian Blackman(Executive Officer)Simon Tulloch(Executive Officer)Stephen Hill(Executive Officer, Director)

BoardPaulina Hill(Director)Steven Gillis(Executive Officer, Director, Promoter)in

Co-investorsARCH Venture Partners Polaris Partners

Fortis Therapeuticsfortistx.com

Fortis Therapeutics develops therapeutic treatments based on technology licensed from UCSF, with a focus on oncology and other disease areas.

BiotechHealthtechMedical DevicesSan Diego, US

Marc Nasoff(Chief Scientific Officer)

BoardJay B. Lichter(Ph.D.)

Co-investorsVivo Capital Lilly Asia Ventures Osage University Partners Avalon BioVentures

Graphite Bio

Hack The Boxhackthebox.com in 𝕏

Hack The Box provides hands-on training and simulation platforms for cybersecurity blue teams, including labs, courses, and incident response exercises designed to develop skills in SOC operations, digital forensics, and threat hunting.

CybersecurityDeveloper ToolsEdTechEnterprise Software

Co-investorsBrighteye Ventures Marathon Venture Capital Paladin Capital Group

HiddenWeights

Homology Medicineshomologymedicines.com

Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.

BiotechBedford, US

Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)

BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)

Co-investors5AM Ventures ARCH Venture Partners Alexandria Deerfield Management Company HBM Healthcare Investments Maverick Ventures +4 more

Hyalexhyalex.com in 𝕏Sep 2024

HYALEX Orthopaedics develops a synthetic cartilage platform for joint repair in orthopaedic surgery.

HealthtechMedical DevicesLexington, US

Carl Vause(Executive Officer, Director)inMira Sahney(Executive Officer, Director)inDavid Myung(Director)

BoardMichael Hawkins(Director)Wende Hutton(Director)inWilliam Harrington(Director)in

Co-investorsCanaan Partners Treo Ventures, Llc

Iconic Therapeutics

BiotechSouth San Francisco, US

Kirk Dornbush(Executive Officer, Director)William Greene(Executive Officer, Director)

BoardJohan Kordel(Director)Bruce Robertson(Director)Todd Foley(Director)Peter Hirth(Director)

Immune Designimmunedesign.com

BiotechSeattle, US

Carlos V. Paya(Executive Officer, Director)Ed Penhoet(Director)Stephen R. Brady(Executive Officer)Jan Henrik ter Meulen(Executive Officer)David Baltimore(Director)William Ringo(Director)

Co-investorsSanofi Ventures

Infinite Uptimeinfinite-uptime.com in 𝕏Dec 2016

Infinite Uptime builds PlantOS, a prescriptive AI platform for heavy manufacturing that reads mechanical and process-induced fault signatures to tell plant operators which equipment fault to fix, why, and by when.

Advanced ManufacturingAI & Machine LearningIoTMenlo Park, US

Raunak Bhinge(Executive Officer, Director)inJean-David Margulici(Executive Officer, Director)

Co-investorsDorm Room GiTV, Inc.TDK Ventures Trifecta Capital Advisors VenturEast Avataar Venture Partners +1 more

Interius BioTherapeutics

BiotechPhiladelphia, US

Philip R. Johnson, M.D.(Executive Officer, Director)Dora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)

BoardTomas Kiselak(Director)

Co-investorsPfizer Venture Investments

KenScikensci.comAcquired

Vertically-integrated machine learning platform for healthcare powering transition to value-based care with predictive analytics.

Co-investorsMindset Venture Osage University Partners

Kolltan Pharmaceuticals

BiotechNew Haven, US

Joseph Schlessinger(Director)Michael Schmertzler(Executive Officer, Director)Stanley Choy(Executive Officer)Yaron Hadari(Executive Officer)W. Bradford Middlekauff(Executive Officer)

BoardAxel Bolte(Director)

Kymetakymetacorp.com in

Kymeta develops flat-panel satellite antennas and connectivity terminals, including its u5 and u8 product lines, that switch between LEO and GEO networks for mobile land and maritime use.

Defense TechHardwareSpace TechRedmond, US

Marc Stolzman(Executive Officer)inBill Marks(Executive Officer)Keith Cochran(Executive Officer)inManny Mora(President and CEO)inAnne(Chief Financial Officer)inRyan(Chief Scientist)in

Co-investorsLux Capital Manta Ray Ventures Tectonic Ventures Osage University Partners

Landos BiopharmaAug 2019

BiotechBlacksburg, US

Josep Bassaganya-Riera(Executive Officer, Director)Christopher Garabedian(Director)

LunaDNA

Luxteraluxtera.com

Global leader in silicon photonics, first to achieve direct 'fiber to the chip' integration on CMOS.

Carlsbad, US

Eli Yablonovitch(Director)Greg Young(Executive Officer, Director)Tom Foody(Executive Officer)

BoardAndy Rappaport(Director)Rohini Chakravarthy(Director)Forest Baskett(Director)

Co-investorsAugust Capital Cisco Investments TEL Venture Capital, Inc.

MC10mc10inc.com in 𝕏acquired by Medidata

MC10 developed conformal BioStamp wearable sensors and clinical analytics for physiological data capture in clinical research.

BiotechDigital HealthHealthtechMedical DevicesLexington, US

John Rogers(Director)David Icke(Executive Officer, Director)Alice Sansone(Executive Officer)Steven N. Tannenbaum(Executive Officer)Scott D. Pomerantz(Executive Officer, Director)

BoardMarc Singer(Director)in

Co-investorsBraemar Energy Ventures Mitsui Global Investment Windham Capital Partners North Bridge Venture Partners

MediSix Therapeutics

Singapore-based immune engineering company developing novel cellular therapies for T-cell malignancies and autoimmune diseases.

Singapore

Co-investorsClavystBio Lightstone Ventures

Menlo Securitymenlosecurity.com in 𝕏

Menlo Security provides a browser security platform that protects both human users and AI agents through a hybrid architecture combining local security controls with cloud-based threat protection.

AI & Machine LearningCybersecurityEnterprise SoftwareMountain View, US

Amir Ben-Efraim(Founder)Poornima DeBolle(Founder)

Co-investorsBaruch Future Ventures Engineering Capital Junipero

Metalenzmetalenz.com in 𝕏

Metalenz develops metasurface optics technology for optical sensing in consumer and industrial devices.

Deep TechHardwareSemiconductorsStoneham, US

Federico Capasso(Director)Rob Devlin(Founder)in

BoardXuhui Shao(Director)in

Co-investorsBantam Group Braemar Energy Ventures Foothill Ventures Global Brain Intel Capital M Ventures +7 more

Millendo Therapeutics

Co-investorsLongwood Fund

Mobiamedicalmobia.com in 𝕏

Mobia Medical (formerly MicroTransponder) develops Vivistim Paired VNS Therapy, an FDA-approved vagus nerve stimulation treatment for chronic ischemic stroke survivors with moderate to severe upper extremity impairment.

HealthtechMedical Devices

Jordan Curnes(Co-Founder)

Co-investorsGreen Park & Golf Ventures US Venture Partners

Modis Therapeutics

Co-investorsF-Prime Capital

Neuros

Nocion Therapeuticsnociontx.com in 𝕏

Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.

BiotechHealthtechMedical DevicesWatertown, US

MATTHEW FRANKEL(Executive Officer)inPETER COUROSSI(Executive Officer)RICHARD BATYCKY(Executive Officer, Director)JAMES ELLIS(Executive Officer)MICHAEL LIPP(Executive Officer)inCHRISTOPHER SILBER(Executive Officer)in

Co-investorsCanaan Partners F-Prime Capital Mission Biocapital Monograph Capital Partners Osage University Partners

Normunity

NuMat

Opsysopsys-tech.com in

Opsys develops solid-state scanning LiDAR sensors with no moving parts, using VCSEL and SPAD chip technology for autonomous driving and industrial applications.

AI & Machine LearningDeep TechHardwareRoboticsIsrael, IL

Co-investors83North Saban Ventures TransLink Capital Osage University Partners

Otonomy

Overland Aioverland.ai

Overland AI develops ground autonomy solutions for military vehicles and land operations, enabling autonomous mobility without human operators.

AI & Machine LearningDefense TechRoboticsSeattle, US

Byron Boots(Co-Founder & CEO)inStephanie Bonk(Co-Founder & President)inGreg Okopal(Co-Founder & COO)inJonathan Fink(Executive Officer)

BoardChristopher Morales(Director)

Co-investors8VC Ascend Venture Capital Point72 Ventures Voyager Capital Cubit Capital Shasta Ventures +3 more

Palladio BiosciencesSep 2020

BiotechHorsham, US

Lorenzo Pellegrini(Executive Officer, Director)Marella Thorell(Executive Officer)John Alexander Martin(Executive Officer, Director)Sanford Zweifach(Director)Frank Condella(Director)

BoardFrancesco DeRubertis(Director)

Perceptive AutomataSep 2018

Somerville, US

Samuel Anthony(Executive Officer, Director)Kshitij Misra(Executive Officer, Director)John Harris(Director)

Picwellpicwell.com in 𝕏Acquired

Picwell operates ALEX, a benefits decision-support platform that combines plan recommendations, enrollment, benefits administration, and year-round guidance for employees.

HR TechInsurTechSaaSPhiladelphia, US

Thomas Baker(Executive Officer, Director)Jonathan Thompson Kolstad(Executive Officer, Director)Robert James Town(Executive Officer, Director)Jay Silverstein(Executive Officer, Director)Anirudh Vemprala(Executive Officer, Director)

BoardKevin Hill(Director)

Co-investorsBlue Venture Funds MassMutual Ventures Osage University Partners

Pionyr Immunotherapeuticspionyrtx.com in

HealthtechSan Francisco, US

Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)inLeon Chen, Ph.D.(Director)Carol Gallagher(Director)Joshua Resnick, M.D.(Director)

BoardMichael Powell(Director)

Co-investorsMission Bay Capital Mission Biocapital New Enterprise Associates (NEA)Sofinnova Ventures Sofinnova Venture Partners

PMV Pharmapmvpharma.comFeb 2017

PMV Pharma develops precision oncology therapies that target and structurally correct mutated p53 proteins to restore their tumor-suppressing function.

BiotechHealthtechCranbury, US

David H. Mack, Ph.D.(Founder)inDavid Mack(Executive Officer, Director)Arnold Levine(Director)

BoardPeter Thompson(Director)Steve Winick(Director)Arnold Oronsky(Director)

Co-investorsAvoro Capital Advisors Nextech Invest RA Capital OrbiMed Osage University Partners

Precedeprecede.bio in 𝕏

Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.

AI & Machine LearningBiotechDigital HealthBoston, US

Rehan Verjee(Co-Founder, Chief Executive Officer, Board Director)Sylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)Toni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)

Co-investorsIllumina Ventures 5AM Ventures Lilly Asia Ventures Osage University Partners

Quantum Circuitsquantumcircuits.com inAcquired

Quantum Circuits develops superconducting quantum computers using dual-rail qubits with built-in error detection, designed to accelerate the path to fault-tolerant quantum computing.

Advanced ManufacturingDeep TechHardwareQuantum ComputingMadison, US

Rob Schoelkopf(Sterling Professor, Founder)Luigi FrunzioRay Smets

Co-investorsARCH Venture Partners Canaan Partners Connecticut Innovations F-Prime Capital Fitz Gate Ventures Tribeca Venture Partners

Quintessentquintessent.com

Quintessent develops optical connectivity solutions to address chip-to-chip communication bottlenecks in large-scale computing and AI systems.

AI & Machine LearningCloud ComputingDeep TechHardwareSemiconductorsSanta Barbara, US

Alan Liu(CEO, Co-Founder & Board Member)inBrian Koch(VP of Engineering & Co-Founder)inJohn Bowers(Chairman of the Board & Co-Founder)

Co-investorsEntrada Ventures Foothill Ventures M Ventures Sierra Ventures

Receptosreceptos.com inFeb 2012Acquired

San Diego biopharmaceutical company developing GPCR-targeted immune-inflammatory drugs; acquired by Celgene for ~$7.2B in 2015.

BiotechSan Diego, US

Marcus Boehm(Executive Officer)Robert Peach(Executive Officer)inRaymond Stevens(Director)Faheem Hasnain(Executive Officer, Director)James Schmidt(Executive Officer)Chrysa Mineo(Executive Officer)

Co-investorsARCH Venture Partners Venrock

ReCode Therapeuticsrecodetx.com in 𝕏

ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)

Co-investorsAju IB Invesment Corporation EcoR1 Capital Evolution VC Partners MPM BioImpact OrbiMed Pfizer Venture Investments +6 more

Redonaredonatx.com in

Redona Therapeutics is a drug discovery company co-founded by Harvard Medical School investigators focused on novel areas of biology.

AI & Machine LearningBiotechBoston, US

George Daley(Co-founder)Richard Gregory(Co-founder)Frank Slack(Co-founder)Piotr Sliz(Co-founder)Kazumi Shiosaki(President & CEO)

Co-investorsAstellas Venture Management LLC Sofinnova Partners

Resolv Technology

Ribon Therapeutics in

BiotechLexington, US

Victoria M. Richon(Executive Officer, Director)in

BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)

Co-investorsAvego BioScience Capital Peregrine Ventures AbbVie Novartis Venture Fund The Column Group

Sana Biotechnologysana.com in

Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.

BiotechHealthtechMedical DevicesSeattle, US

Steve Harr(President and Chief Executive Officer)

Co-investorsAmerican Family Ventures ARCH Venture Partners F-Prime Capital Flagship Pioneering Innovating Capital JDRF T1D Fund +1 more

Satsuma Pharmaceuticalssatsumarx.com

Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101).

BiotechHealthtechMedical DevicesSouth San Francisco, US

John Kollins(Executive Officer, Director)Tadayoshi Iwashima(Executive Officer)Thomas B. King(President and Board Director)Rob Janosky(Chief Commercial Officer)Tom O'Neil(Chief Financial Officer)David Prichard(Chief Operating Officer)

Co-investorsVivo Capital Red Tree Venture

Seismos

Selecta Biosciences

Co-investorsBoutique Venture Partners venBio Partners

SiFivesifive.com in 𝕏

SiFive develops processor IP based on the open-standard RISC-V instruction set architecture, offering customizable and scalable chip designs.

Deep TechHardwareSemiconductorsSan Francisco, US

Yunsup Lee(Executive Officer, Director)inKrste Asanovic(Director)inAndrew WatermaninStefan A Dyckerhoff(Executive Officer, Director)inNaveed Sherwani(Executive Officer)inPatrick Little(CEO)in

Co-investorsBerkeley SkyDeck Fund Coatue Management Intel Capital Prosperity7 Ventures Qualcomm Ventures Atreides Management +6 more

Snowcap Computesnowcapcompute.com inJun 2025

Snowcap Compute develops superconducting computing platforms using Josephson Junctions to replace semiconductor transistors, delivering orders-of-magnitude greater energy efficiency for AI and high-performance computing workloads.

AI & Machine LearningDeep TechSemiconductorsSan Francisco, US

Anna Herr(Executive Officer)Quentin Herr(Executive Officer)inMichael Shamus Lafferty(Executive Officer, Director)

BoardPat Gelsinger(Director)inRichard Hyman(Director)

Co-investorsPlayground Global Cambium Capital Page One Ventures

Sonoma Biotherapeuticssonomabio.com in 𝕏Jul 2021

Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Jeffrey Bluestone(Executive Officer, Director, Promoter)in

BoardFan Yu(Director)Maggie Wilderotter(Director)Toni Hoover(Director)Terry Rosen(Director)Richard Klausner(Director)

Co-investors8VC ARCH Venture Partners Frazier Life Sciences JDRF T1D Fund LAV Lifeforce Capital +1 more

Streetlight Datastreetlightdata.com in 𝕏

StreetLight provides big data analytics for transportation planning and infrastructure investment decisions.

Climate TechData & InfrastructureGovTechLogistics & Supply ChainMobility & TransportationSan Francisco, US

Paul Friedman(Founder, Chief Technology Officer)inLaura Schewel(Executive Officer, Director, Promoter)in

BoardBill Perry(Director)Scott Pinizzotto(Director)Marc Singer(Director)inDarlene Mann(Director)

Co-investorsACTIVATE CAPITAL PARTNERS

Synthorxacquired by Sanofi

Clinical-stage biotech expanding the genetic alphabet with synthetic nucleotides; acquired by Sanofi for $2.5B in 2020.

BiotechLa Jolla, US

Floyd Romesberg(Director)Douglas Downs(Executive Officer)

BoardJay Lichter(Director)Court Turner(Executive Officer, Director)

Co-investorsAvalon BioVentures Boutique Venture Partners Correlation Ventures RA Capital venBio Partners Medicxi +1 more

Tessera Labstesseralabs.ai in 𝕏

Tessera provides a multi-agent AI platform for enterprise system modernization, automating processes across ERP, CRM, HCM, and finance systems with governed execution.

AI & Machine LearningEnterprise SoftwareSaaS

Kabir Nagrecha(Chief Executive Officer)inMing Chang(Chief Operating Officer)inAnirudh Sriram(Chief Technology Officer)inPrakash Gupta(Chief Revenue Officer)in

Co-investorsAndreessen Horowitz Foundation Capital Myriad Venture Partners Osage University Partners

Tessera Labs

Thumbnail for Escient Pharmaceuticalsescientpharma.com

BiotechSan Diego, US

Alain Baron(Executive Officer, Director)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Executive Officer)

BoardAndrew Schwab(Director)in

Co-investors5AM Ventures Avego BioScience Capital New Enterprise Associates (NEA)Sanofi Ventures The Column Group Abingworth +3 more

Trellis Airtrellisair.com in 𝕏Mar 2025

Somerville, US

Russ Wilcox(Executive Officer, Director)

BoardCraig Shapiro(Director)

Co-investorsWorkshop Venture Partners

Urjaneturjanet.com in 𝕏

Arcadia (urjanet.com) offers a platform that unifies utility bill and interval data, tariff and energy rate calculations, and solar and storage analysis into energy data and analytics.

CleantechClimate TechData & InfrastructureEnergyAtlanta, US

SANJOY MALIK(Executive Officer, Director)in

BoardPETER KIGHT(Director)STEVE FREDRICK(Director)inSIG MOSLEY(Director)DAVID RATCLIFFE(Director)

Co-investorsCorrelation Ventures Grotech Ventures Oak HC/FT

Vanqua Bio

Verdox

Develops electroswing adsorption technology for scalable and cost-effective carbon capture and removal

Co-investorsAzolla Ventures LOWERCARBON Lowercarbon Capital

Verve Motionvervemotion.com in 𝕏

Verve Motion develops the SafeLift exosuit, a wearable device designed to reduce workplace injuries and increase productivity for physically demanding jobs.

Future of WorkHardwareLogistics & Supply ChainRobotics

Ignacio Galiana(Founder)in

Co-investorsConstruct Capital Cybernetix Ventures Founder Collective Pillar VC Safar Partners

Virtue Aivirtueai.com in 𝕏

Virtue AI offers an enterprise AI security platform that applies real-time guardrails, red-teaming, and compliance controls to AI models and agentic systems.

AI & Machine LearningCybersecurityEnterprise SoftwareSan Francisco, US

Sanmi Koyejo(Founder)

Co-investorsWalden Catalyst

Xscape Photonicsxscapephotonics.com in

Fort Lee, US

Alexander Gaeta(Executive Officer, Director)inVivek Raghunathan(Executive Officer, Director)inYoshitomo Okawachi(Executive Officer)Alexander Kash(Executive Officer, Director)

BoardJames Scapa(Director)

Co-investorsCisco Investments Fathom Fathom Fund IAG Capital Partners LifeX Ventures NVIDIA

Exits · 15

IPOs and acquisitions across the tracked portfolio

AmbiqNYSE: AMBQBeam TherapeuticsNASDAQ: BEAMEvolv TechnologiesNASDAQ: EVLVGuardant HealthNASDAQ: GHIonQNYSE: IONQKura OncologyNASDAQ: KURAPrecision BioSciencesNASDAQ: DTILPrime MedicineNASDAQ: PRMEQ32 BioNASDAQ: QTTBSera PrognosticsNASDAQ: SERASpero TherapeuticsNASDAQ: SPROVeradermicsNYSE: MANEVor BiopharmaNASDAQ: VORMC10acq. by MedidataSynthorxacq. by Sanofi

Portfolio news

latest coverage across their companies

Sera Prognostics Still Needs Revenue Proof to Match Its Clinical Momentum - Alphastreet

Sera Prognostics · news.alphastreet.com · Aug 20, 2026

Alphabet Inc. Makes New Investment in Spero Therapeutics, Inc. $SPRO

Spero Therapeutics · marketbeat.com · Aug 18, 2026

KenSci Secures $22M in Funding for AI-Powered Risk Prediction Platform | Chief Healthcare Executive

KenSci · chiefhealthcareexecutive.com · Aug 17, 2026

InduPro raises $77M, begins first human trial of cancer drug – GeekWire

Ribon Therapeutics · geekwire.com · Aug 14, 2026

Precision BioSciences Q2 2026 results: Warrant revaluation widens the net loss

Precision BioSciences · tradingkey.com · Aug 6, 2026

Q32 Bio boosts cash as losses narrow modestly | QTTB Quarterly Report (10-Q)

Q32 Bio · stocktitan.net · Aug 5, 2026

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Beam Therapeutics · globenewswire.com · Aug 4, 2026

Veradermics Tumbles as Lock-Up Expiry Spooks Investors - TipRanks.com

Veradermics · tipranks.com · Aug 3, 2026

Frequently asked questions

How many investments has OUP (Osage University Partners) made?: OUP (Osage University Partners) has 118 tracked investments, 9 of which have exited via acquisition or IPO, including 3 dated in the last 24 months.
What stage does OUP (Osage University Partners) invest at?: OUP (Osage University Partners) invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is OUP (Osage University Partners)'s typical check size?: OUP (Osage University Partners) typically writes checks of $1M – $20M.
What sectors does OUP (Osage University Partners) focus on?: OUP (Osage University Partners) focuses on AI & Machine Learning, Biotech, Cleantech, Climate Tech, Cloud Computing, Cybersecurity, Deep Tech, Digital Health, Energy, Enterprise Software, Hardware, Healthtech, Medical Devices, New Materials, Quantum Computing, SaaS, Sector Agnostic, Semiconductors.
Where is OUP (Osage University Partners) located?: OUP (Osage University Partners) is headquartered in Bala Cynwyd, US.
Does OUP (Osage University Partners) lead rounds?: Yes, OUP (Osage University Partners) leads investment rounds.
Who does OUP (Osage University Partners) co-invest with?: OUP (Osage University Partners) most often shares deals with ARCH Venture Partners, F-Prime Capital, Canaan Partners, among 198 tracked co-investors.

Media · Podcasts & interviews

featuring the team

University Spinouts and Deep Tech Investing | Marc Singer | Osage University Partners (OUP)

Deep Tech Leaders · Marc Singer

Ventures #15 w/ Matt Cohen - Managing Partner @ Osage University Partners (OUP) | BIOS

BIOS · Matt Cohen

Founder's Equity: Formation, Dilution, Industry Averages - Manny Stockman, Osage University Partners

UCLA TDG · Manny Stockman

Marc Singer, John Lee (Osage University Partners)

Marc Singer · vimeo.com

Advisory Boards in Academic Innovation: Three University Models

Osage University Partners

SBIR/STTR Reauthorization: Tips and Tricks for Navigating New Funding Opportunities

Osage University Partners

Images

Co-investors · 47

Canaan Partners

Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.

Both backed · 6

Alphina Therapeutics Antiva Biosciences Arrakis Therapeutics Hyalex Nocion Therapeutics Quantum Circuits

$500K – $20M

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 5

Clarifai Everactive Metalenz Pionyr Immunotherapeutics Thumbnail for Escient Pharmaceuticals

$200K – $40M

OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 5

Q32 Bio Delfi Diagnostics PMV Pharma ReCode Therapeutics Synthorx

$1M – $75M

5AM Ventures

5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.

Both backed · 4

Vor BiopharmaHomology Medicines Precede Thumbnail for Escient Pharmaceuticals

$100K – $4M

Lux Capital

Lux Capital is a venture capital firm that backs founders building transformative deep technologies, having been among the first investors in category-defining companies across AI, robotics, biotech, defense, and infrastructure.

Both backed · 3

Evolv Technologies Clarifai Kymeta

$100K – $100M

MPM BioImpact

MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.

Both backed · 3

Antiva Biosciences Blade Therapeutics ReCode Therapeutics

$1M – $15M

Nextech Invest

Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.

Both backed · 3

Kura Oncology Arrakis Therapeutics PMV Pharma

$648K – $3.2M

Agent Capital

Agent Capital is a healthcare venture capital firm that invests in novel, differentiated therapeutics and treatments addressing unmet patient needs across all stages of development.

Both backed · 3

Precision BioSciences Q32 Bio Aptinyx

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

Both backed · 2

Guardant Health eGenesis

$5K – $50M

US Venture Partners

US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.

Both backed · 2

Effector Therapeutics Mobiamedical

$500K – $10M

Deerfield Management Company

Deerfield Management is a healthcare-focused investment firm that supports companies across the healthcare ecosystem through flexible funding, market intelligence, and philanthropic initiatives.

Both backed · 2

Dracenpharma Homology Medicines

The Column Group

The Column Group (TCG) is a venture capital firm focused on building and backing biotechnology companies, applying an edge-to-edge investment model centered on company formation with capacity for long-term private and public capital support.

Both backed · 2

Ribon Therapeutics Thumbnail for Escient Pharmaceuticals

$30M

▶35 more co-investors

Hatteras Venture Partners Braemar Energy Ventures Madrona Venture Group Sierra Ventures G2 Venture Partners MassMutual Ventures Engineering Capital SR One Capital Management Domain Associates APERTURE Venture Partners General Catalyst Bessemer Venture Partners Plug and Play Ventures Company Capital Javelin Venture Partners American Express Ventures (Amex)Breakthrough Energy Ventures JAZZ Venture Partners EQT Life Sciences Gutbrain Ventures Versant Ventures Johnson & Johnson Innovation – JJDC Deep Fork Capital Calibrate Ventures Venture Guides Management, L.P.Pivotal Life Sciences Newfund Capital Amara VC Omega Funds RiverVest Venture Partners Medical Excellence Capital Chrysalix Aberdare Ventures BrightCap Investment Advisor AD Signet Healthcare Partners

Firms observed investing alongside OUP (Osage University Partners), from public investor directories. Shared companies are the overlap with OUP (Osage University Partners)'s recorded portfolio.

Similar investors

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

$5K – $50M

Everywhere Ventures

Everywhere Ventures is an early-stage venture firm, backed by a community of founders and operators as LPs, that writes early checks (including pre-seed) into startups across many sectors and geographies.

$250K

BDC Fund Investments (Fund-of-Funds)

BDC (Business Development Bank of Canada) is a bank supporting Canadian small and medium-sized businesses across all industries and growth stages with financing and advisory services.

Maverick Ventures Israel

Maverick Ventures Israel is an early-stage venture capital firm founded by entrepreneurs, backing Israeli technology startups across diverse industries with capital and operational support.

$2M – $5M

Featured in lists

Investors & VC Firms in North America Investors & VC Firms in United States Seed Investors & VC Firms Series A Investors & VC Firms Pre-Seed Investors & VC Firms Seed Investors & VC Firms in North America Seed Investors & VC Firms in United States Growth Investors & VC Firms Series A Investors & VC Firms in North America Series B Investors & VC Firms Series A Investors & VC Firms in United States Investors & VC Firms in Global